跳至主要内容
临床试验/JPRN-UMIN000005862
JPRN-UMIN000005862招募中2 期

A phase 2 study, investigating prevention and treatment algorism of the skin toxicity related with Panitumumab treatment in patients with unresectable and/or metastatic CRC with KRAS wild type refractory to 5-FU containing chemotherapy - A phase 2 study, investigating prevention and treatment algorism of the skin toxicity related with Panitumumab treatment in patients with unresectable and/or metastatic CRC with KRAS wild type refractory to 5-FU containing chemotherapy

ational Cancer Center Hospital East0 个研究点目标入组 40 人开始时间: 2011年6月28日最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who have central nervous system metastasis, homozygote of UGT1A1 *28 or *6, double heterozygote of UGT1A1 *28 and *6, prior anti-EGFR therapy, unresolved toxicities from prior anthi-cancer therapy, clinically significant complication, pre- or co-existing interstitial pneumoniae, do not consent to use adequate contraceptive precausions with child-bearing potential, are breast-feeding or pregnant female.

研究者

发起方
ational Cancer Center Hospital East

相似试验